To review the use of aripiprazole in children and adolescents.
Methods:
Medline and Embase databases were systematically searched using the keywords aripiprazole and child or adolescent over the period from 2000 to 2019. The initial screen yielded 163 publications, from which 99 studies were reviewed.
Results:
Aripiprazole is one of the most widely prescribed atypical antipsychotics. Like others, its use in children and adolescents is becoming commonplace and occurs in off-label indications. Aripiprazole has proven efficacy for several indications in children and adolescents, including schizophrenia, bipolar disorder, Tourette's syndrome, and behavioral impairments associated with autism and intellectual disability. Adverse effects are more important in children and adolescents than adults, particularly weight gain, drowsiness, extrapyramidal effects, and metabolic effects, even though the latter may appear less important than with other atypical antipsychotics. Severe adverse effects often occur in multiple-prescription settings. At present, postprescription monitoring is very poor.
Conclusion:
Aripiprazole has proven efficacy for several indications in children and adolescents. However, its use requires clinical and paraclinical monitoring to assess the occurrence of adverse events that may challenge the benefit/risk ratio. In addition, off-label prescriptions should be limited, as they appear to account for a significant proportion of aripiprazole use worldwide.
Get full access to this article
View all access options for this article.
References
1.
Akyol ArdicU, ErcanES, KutluA, YuceD, IpciM, InciSB: Successful treatment response with aripiprazole augmentation of SSRIs in refractory obsessive-compulsive disorder in childhood. Child Psychiatry Hum Dev, 48:699–704, 2017.
2.
Al-DhaherZ, KapoorS, SaitoE, KrakowerS, DavidL, AkeT, KaneJM, CorrellCU, CarbonM: Activating and tranquilizing effects of first-time treatment with aripiprazole, olanzapine, quetiapine, and risperidone in youth. J Child Adolesc Psychopharmacol, 26:458–470, 2016.
3.
AlmandilNB, LiuY, MurrayML, BesagFMC, AitchisonKJ, WongICK: Weight gain and other metabolic adverse effects associated with atypical antipsychotic treatment of children and adolescents: A systematic review and meta-analysis. Paediatr Drugs, 15:139–150, 2013.
4.
BachmannCJ, LemppT, GlaeskeG, HoffmannF: Antipsychotic prescription in children and adolescents. Dtsch Ärztebl Int, 111:25–34, 2014.
5.
Bénard-LaribièreA, NoizeP, GirodetPO, LassalleR, Dureau-PourninC, Droz-PerroteauC, Fourrier-RéglatA, SalvoF, BezinJ, ParienteA; DRUGS-2M Study Group: Monitoring of drug misuse or potential misuse in a nationwide healthcare insurance database: A cross-sectional study in France. Therapie, 74:469–476, 2019.
6.
BiniciNC, GüneySA: Epistaxis as an unexpected side effect of aripiprazole and risperidone treatment in two children with two different psychiatric diagnosis. J Child Adolesc Psychopharmacol, 27:759–760, 2017.
7.
BoyerMG, KheloufiF, DenisJ, MicallefJ, MilhM: Urinary retention associated with aripiprazole: Report of a new case and review of the literature. Therapie, 73:287–289, 2018.
8.
CarbonM, KapoorS, SheridanE, Al-JadiriA, AzzoS, SarkariaT, KaneJM, SaitoE, CorrellCU: Neuromotor adverse effects in 342 youth during 12 weeks of naturalistic treatment with 5 second-generation antipsychotics. J Am Acad Child Adolesc Psychiatry, 54:718.e3–727.e3, 2015.
9.
ChenW, Cepoiu-MartinM, StangA, DuncanD, SymondsC, CookeL, PringsheimT: Antipsychotic prescribing and safety monitoring practices in children and youth: A population-based study in Alberta, Canada. Clin Drug Investig, 38:449–455, 2018.
10.
ClavennaA, AndrettaM, PilatiP, DusiM, GangemiM, GattoniMB, LombardoG, ZoccanteL, MezzaliraL, BonatiM: Antidepressant and antipsychotic use in an Italian pediatric population. BMC Pediatrics, 11:40, 2011.
11.
CohenD, BonnotO, BodeauN, ConsoliA, LaurentC: Adverse effects of second-generation antipsychotics in children and adolescents: A Bayesian meta-analysis. J Clin Psychopharmacol, 32:309–316, 2012.
12.
CohenD, RaffinM, CanitanoR, BodeauN, BonnotO, PérisseD, ConsoliA, LaurentC: Risperidone or aripiprazole in children and adolescents with autism and/or intellectual disability: A Bayesian meta-analysis of efficacy and secondary effects. Res Autism Spectr Disord, 7:167–175, 2013.
13.
CoughlinM, GoldieCL, TranmerJ, Khalid-KhanS, TregunnoD: Patient, treatment, and health care utilization variables associated with adherence to metabolic monitoring practices in children and adolescents taking second-generation antipsychotics. Can J Psychiatry, 63:240–249, 2018.
14.
CraveroC, GuinchatV, Claret-TournierA, SahnounC, BonniauB, BodeauN, Danion-GrilliatA, CohenD, ChamakB: Drug treatments received by children, adolescents and young adults with autism spectrum disorder in France: a state of play based on parental experience. Neuropsychiatr Enfance Adolesc, 16:33–41, 2017.
15.
CrystalS, OlfsonM, HuangC, PincusH, GerhardT: Broadened use of atypical antipsychotics: Safety, effectiveness, and policy challenges. Health Aff (Millwood), 28:w770–w781, 2009.
16.
De HertM, DobbelaereM, SheridanEM, CohenD, CorrellCU: Metabolic and endocrine adverse effects of second-generation antipsychotics in children and adolescents: A systematic review of randomized, placebo controlled trials and guidelines for clinical practice. Eur. Psychiatry, 26:144–158, 2011.
17.
DiomšinaB, RasmussenPD, DanilevičiütėV: Clinical experience of long-term treatment with Aripiprazole (Abilify) in children and adolescents at the child and adolescent psychiatric clinic 1 in Roskilde, Denmark. Acta Pol Pharm, 72:597–606, 2015.
18.
DosreisS, YoonY, RubinDM, RiddleMA, NollE, RothbardA: Antipsychotic treatment among youth in foster care. Pediatrics, 128:e1459–e1466, 2011.
19.
ErcanES, ArdicUA, ErcanE, YuceD, DurakS: A promising preliminary study of aripiprazole for treatment-resistant childhood obsessive-compulsive disorder. J Child Adolesc Psychopharmacol, 25:580–584, 2015.
20.
ErcanES, UysalT, ErcanE, Akyol ArdicU, ArdıcUA: Aripiprazole in children and adolescents with conduct disorder: A single-center, open-label study. Pharmacopsychiatry, 45:13–19, 2012.
21.
FallahMS, ShaikhMR, NeupaneB, RusieckiD, BennettTA, BeyeneJ: Atypical antipsychotics for irritability in pediatric autism: A systematic review and network meta-analysis. J Child Adolesc Psychopharmacol, 29:168–180, 2019.
22.
FatimaS, MottolaN: Case 5: A 7-year-old autistic boy with altered movements and mental status. Pediatr Rev, 38:493, 2017.
23.
FindlingRL, CorrellCU, NyilasM, ForbesRA, McQuadeRD, JinN, IvanovaS, MankowskiR, CarsonWH, CarlsonGA: Aripiprazole for the treatment of pediatric bipolar I disorder: A 30-week, randomized, placebo-controlled study. Bipolar Disord, 15:138–149, 2013.
24.
FindlingRL, KauffmanR, SalleeFR, SalazarDE, SahasrabudheV, KolliaG, KornhauserDM, VachharajaniNN, Assuncao-TalbottS, MallikaarjunS, IwamotoT, McQuadeRD, BoultonDW, BlumerJ: An open-label study of aripiprazole: Pharmacokinetics, tolerability, and effectiveness in children and adolescents with conduct disorder. J Child Adolesc Psychopharmacol, 19:431–439, 2009.
25.
FindlingRL, MankoskiR, TimkoK, LearsK, McCartneyT, McQuadeRD, EudiconeJM, AmatniekJ, MarcusRN, SheehanJJ: A randomized controlled trial investigating the safety and efficacy of aripiprazole in the long-term maintenance treatment of pediatric patients with irritability associated with autistic disorder. J Clin Psychiatry, 75:22–30, 2014.
26.
FindlingRL, McNamaraNK, YoungstromEA, StansbreyRJ, FrazierTW, LinglerJ, OttoBD, DemeterCA, RowlesBM, CalabreseJR: An open-label study of aripiprazole in children with a bipolar disorder. J Child Adolesc Psychopharmacol, 21:345–351, 2011.
27.
FindlingRL, RobbA, NyilasM, ForbesRA, JinN, IvanovaS, MarcusR, McQuadeRD, IwamotoT, CarsonWH: A multiple-center, randomized, double-blind, placebo-controlled study of oral aripiprazole for treatment of adolescents with schizophrenia. Am J Psychiatry, 165:1432–1441, 2008a.
28.
FindlingRL, ShortEJ, LeskovecT, TownsendLD, DemeterCA, McNamaraNK, StansbreyRJ: Aripiprazole in children with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol, 18:347–354, 2008b.
29.
FindlingRL, YoungstromEA, McNamaraNK, StansbreyRJ, WynbrandtJL, AdegbiteC, RowlesBM, DemeterCA, FrazierTW, CalabreseJR: Double-blind, randomized, placebo-controlled long-term maintenance study of aripiprazole in children with bipolar disorder. J Clin Psychiatry, 73:57–63, 2012.
30.
FindlingRL, YoungstromEA, RowlesBM, DeylingE, LinglerJ, StansbreyRJ, McVoyM, LytleS, CalabreseJR, McNamaraNK: A double-blind and placebo-controlled trial of aripiprazole in symptomatic youths at genetic high risk for bipolar disorder. J Child Adolesc Psychopharmacol, 27:864–874, 2017.
31.
FungLK, MahajanR, NozzolilloA, BernalP, KrasnerA, JoB, CouryD, WhitakerA, Veenstra-VanderweeleJ, HardanAY: Pharmacologic treatment of severe irritability and problem behaviors in autism: A systematic review and meta-analysis. Pediatrics 137(Suppl, 2):S124–S135, 2016.
32.
GermanòE, ItalianoD, LambertiM, GuerrieroL, PriviteraC, D'AmicoG, SiracusanoR, IngrassiaM, SpinaE, CalabròMP, GaglianoA: ECG parameters in children and adolescents treated with aripiprazole and risperidone. Prog Neuropsychopharmacol Biol Psychiatry, 51:23–27, 2014.
33.
GhanizadehA: Twice-weekly aripiprazole for treating children and adolescents with tic disorder, a randomized controlled clinical trial. Ann Gen Psychiatry, 15:21, 2016.
34.
GhanizadehA, SahraeizadehA, BerkM: A head-to-head comparison of aripiprazole and risperidone for safety and treating autistic disorders, a randomized double blind clinical trial. Child Psychiatry Hum Dev, 45:185–192, 2014.
HoJG, CaldwellRL, McDougleCJ, Orsagh-YentisDK, EricksonCA, PoseyDJ, StiglerKA: The effects of aripiprazole on electrocardiography in children with pervasive developmental disorders. J Child Adolesc Psychopharmacol, 22:277–283, 2012.
41.
HoşoğluE, Bayram Ö, HergünerS: Nasal and gingival bleeding during aripiprazole but not haloperidol treatment. J Child Adolesc Psychopharmacol, 26:950–951, 2016.
42.
IchikawaH, HirataniM, YasuharaA, TsujiiN, OshimoT, OnoH, TadoriY: An open-label extension long-term study of the safety and efficacy of aripiprazole for irritability in children and adolescents with autistic disorder in Japan. Psychiatry Clin Neurosci, 72:84–94, 2018.
43.
IchikawaH, MikamiK, OkadaT, YamashitaY, IshizakiY, TomodaA, OnoH, UsukiC, TadoriY: Aripiprazole in the treatment of irritability in children and adolescents with autism spectrum disorder in Japan: A randomized, double-blind, placebo-controlled study. Child Psychiatry Hum Dev, 48:796–806, 2017.
44.
IşikÜ, Çam RayP: Aripiprazole-induced hoarseness: A case report. Clin Neuropharmacol, 42:55–56, 2019.
45.
JakobsenKD, BruhnCH, PagsbergA-K, Fink-JensenA, NielsenJ: Neurological, metabolic, and psychiatric adverse events in children and adolescents treated with aripiprazole. J Clin Psychopharmacol, 36:496–499, 2016.
46.
JensenKG, JuulK, Fink-JensenA, CorrellCU, PagsbergAK: Corrected QT changes during antipsychotic treatment of children and adolescents: A systematic review and meta-analysis of clinical trials. J Am Acad Child Adolesc Psychiatry, 54:25–36, 2015.
47.
KimH-W, ParkE-J, KimJ-H, Boon-YasidhiV, TarugsaJ, ReyesA, ManaloS, JoungY-S: Aripiprazole for irritability in asian children and adolescents with autistic disorder: A 12-week, multinational, multicenter, prospective open-label study. J Child Adolesc Psychopharmacol, 28:402–408, 2018.
48.
KimuraG, KadoyamaK, BrownJB, NakamuraT, MikiI, NisiguchiK, SakaedaT, OkunoY: Antipsychotics-associated serious adverse events in children: An analysis of the FAERS database. Int J Med Sci, 12:135–140, 2015.
49.
LambertiM, Di RosaG, CucinottaF, PirontiE, GalatiC, GaglianoA: Aripiprazole-induced tardive dyskinesia in 13 years old girl successfully treated with biperiden: A case report. Clin Psychopharmacol Neurosci, 15:285–287, 2017.
50.
LambertiM, SiracusanoR, ItalianoD, AlosiN, CucinottaF, Di RosaG, GermanòE, SpinaE, GaglianoA: Head-to-head comparison of aripiprazole and risperidone in the treatment of ADHD symptoms in children with autistic spectrum disorder and ADHD: A pilot, open-label, randomized controlled study. Paediatr Drugs, 18:319–329, 2016.
51.
LeRigerM, WilliamsJ, Duncan-WiebeG, ShukryM: Acute masseter dystonia in a pediatric patient receiving aripiprazole and methylphenidate following induction of general anesthesia. Paediatr Anaesth, 27:863–864, 2017.
52.
LiuY, NiH, WangC, LiL, ChengZ, WengZ: Effectiveness and tolerability of aripiprazole in children and adolescents with Tourette's disorder: A meta-analysis. J Child Adolesc Psychopharmacol, 26:436–441, 2016.
53.
ManeetonN, ManeetonB, PutthisriS, SuttajitS, LikhitsathianS, SrisurapanontM: Aripiprazole in acute treatment of children and adolescents with autism spectrum disorder: A systematic review and meta-analysis. Neuropsychiatr Dis Treat, 14:3063–3072, 2018.
54.
MankoskiR, StocktonG, ManosG, MarlerS, McQuadeR, ForbesRA, MarcusR: Aripiprazole treatment of irritability associated with autistic disorder and the relationship between prior antipsychotic exposure, adverse events, and weight change. J Child Adolesc Psychopharmacol, 23:572–576, 2013.
55.
MarcusRN, OwenR, KamenL, ManosG, McQuadeRD, CarsonWH, AmanMG: A placebo-controlled, fixed-dose study of aripiprazole in children and adolescents with irritability associated with autistic disorder. J Am Acad Child Adolesc Psychiatry, 48:1110–1119, 2009.
56.
MarcusRN, OwenR, ManosG, MankoskiR, KamenL, McQuadeRD, CarsonWH, Corey-LislePK, AmanMG: Aripiprazole in the treatment of irritability in pediatric patients (aged 6–17 years) with autistic disorder: Results from a 52-week, open-label study. J Child Adolesc Psychopharmacol, 21:229–236, 2011a.
57.
MarcusRN, OwenR, ManosG, MankoskiR, KamenL, McQuadeRD, CarsonWH, FindlingRL: Safety and tolerability of aripiprazole for irritability in pediatric patients with autistic disorder: A 52-week, open-label, multicenter study. J Clin Psychiatry, 72:1270–1276, 2011b.
58.
MatoneM, LocalioR, HuangY-S, dosReisS, FeudtnerC, RubinD: The relationship between mental health diagnosis and treatment with second-generation antipsychotics over time: A national study of U.S. Medicaid-enrolled children. Health Serv Res, 47:1836–1860, 2012.
59.
McLarenJL, CaubleS, BarnettRJ: Aripiprazole induced acute dystonia after discontinuation of a stimulant medication. J Clin Psychopharmacol, 30:77–78, 2010.
60.
McQuireC, HassiotisA, HarrisonB, PillingS: Pharmacological interventions for challenging behaviour in children with intellectual disabilities: A systematic review and meta-analysis. BMC Psychiatry, 15:303, 2015.
61.
MohapatraS: Extrapyramidal side-effects of low-dose aripiprazole in an 11-year-old child. J Neurosci Rural Pract, 7:141–142, 2016.
62.
MontastrucF, Bénard-LaribièreA, NoizeP, PambrunE, Diaz-BazinF, TournierM, BégaudB, ParienteA: Antipsychotics use: 2006–2013 trends in prevalence and incidence and characterization of users. Eur J Clin Pharmacol, 74:619–626, 2018.
63.
NevoON, MehtaSH, ChanV, GillR, KortepeterC, ChaiGP: Pediatric postmarketing pharmacovigilance and drug utilization review: Abilify (aripiprazole). 2017. https://www.fda.gov/media/107289/download (accessed April9, 2019).
64.
OlfsonM, BlancoC, LiuS-M, WangS, CorrellCU: National trends in the office-based treatment of children, adolescents, and adults with antipsychotics. Arch Gen Psychiatry, 69:1247–1256, 2012a.
65.
OlfsonM, CrystalS, HuangC, GerhardT: Trends in antipsychotic drug use by very young, privately insured children. J Am Acad Child Adolesc Psychiatry, 49:13–23, 2010.
66.
OlfsonM, GerhardT, HuangC, LiebermanJA, BoboWV, CrystalS: Comparative effectiveness of second-generation antipsychotic medications in early-onset schizophrenia. Schizophr Bull, 38:845–853, 2012b.
67.
OwenR, SikichL, MarcusRN, Corey-LisleP, ManosG, McQuadeRD, CarsonWH, FindlingRL: Aripiprazole in the treatment of irritability in children and adolescents with autistic disorder. Pediatrics, 124:1533–1540, 2009.
68.
Palanca-MarescaI, Ruiz-AntoránB, Centeno-SotoGA, Forti-BurattiMA, SilesA, UsanoA, Avendaño-SoláC: Prevalence and risk factors of prolonged corrected QT interval among children and adolescents treated with antipsychotic medications: A long-term follow-up in a real-world population. J Clin Psychopharmacol, 37:78–83, 2017.
69.
PanP-Y, FuA-T, YehC-B: Aripiprazole/methylphenidate combination in children and adolescents with disruptive mood dysregulation disorder and attention-deficit/hyperactivity disorder: An open-label study. J Child Adolesc Psychopharmacol, 28:682–689, 2018.
70.
PanigrahiM, PadhySK, RathiR: Aripiprazole monotherapy in an adolescent worsens psychosis. Indian J Pharmacol, 45:195–196, 2013.
71.
PárragaHC, ShermanBC: Acute dystonia after stimulant discontinuation in 2 ADHD children receiving aripiprazole. J Clin Psychopharmacol, 35:480–481, 2015.
72.
PatelH, PatelA, MushtaqS, HaqF, RazaS: Aripiprazole-induced parkinsonism in a child: A case report. Prim Care Companion CNS Disord, 13:PCC.10l01081, 2011.
73.
PerraudinM, CoulonS, WilloquetG, WelniarzB: The off-label prescription in child and adolescent psychiatry. L’information Psychiatrique, 94:101–107, 2018.
74.
PinnakaS, RobertoAJ, GiordanoA, SillerP, LapidusK: Aripiprazole-induced transient morning pseudoneutropenia in an 11-year-old male. J Child Adolesc Psychopharmacol, 26:858–859, 2016.
75.
PoudrouxE, LebrunJ, ClarivetB, BresV, Hillaire-BuysD, Pinzani CentreV. Atypical antipsychotic misuse and adverse events: A review of the French Pharmacovigilance Database. Fund Clin Pharmacol 32(Suppl, 1):22, 2018.
76.
PozziM, PisanoS, MaranoG, CarnovaleC, BravaccioC, RafanielloC, CapuanoA, RossiF, RizzoR, BernardiniR, NobileM, MolteniM, ClementiE, BiganzoliE, RadiceS: Weight-change trajectories of pediatric outpatients treated with risperidone or aripiprazole in a naturalistic setting. J Child Adolesc Psychopharmacol, 29:133–140, 2019.
77.
PringsheimT, HoJ, SarnaJR, HammerT, PattenS: Feasibility and relevance of antipsychotic safety monitoring in children with tourette syndrome: A prospective longitudinal study. J Clin Psychopharmacol, 37:498–504, 2017.
78.
PringsheimT, LamD, ChingH, PattenS: Metabolic and neurological complications of second-generation antipsychotic use in children: A systematic review and meta-analysis of randomized controlled trials. Drug Saf, 34:651–668, 2011a.
79.
PringsheimT, PanagiotopoulosC, DavidsonJ, Ho J; CAMESA GuidelineGroup: Evidence-based recommendations for monitoring safety of second generation antipsychotics in children and youth. J Can Acad Child Adolesc Psychiatry, 20:218–233, 2011b.
80.
RaebelMA, PenfoldR, McMahonAW, ReichmanM, ShetterlyS, GoodrichG, AndradeS, CorrellCU, GerhardT: Adherence to guidelines for glucose assessment in starting second-generation antipsychotics. Pediatrics, 134:e1308–e1314, 2014.
81.
RafanielloC, PozziM, PisanoS, FerrajoloC, BertellaS, SportielloL, CarnovaleC, SulloMG, CattaneoD, GentiliM, RizzoR, PascottoA, ManiE, VillaL, RiccioMP, SperandeoS, BernardiniR, BravaccioC, ClementiE, MolteniM, RossiF, RadiceS, CapuanoA: Second generation antipsychotics in “real-life”. paediatric patients. Adverse drug reactions and clinical outcomes of drug switch. Expert Opin Drug Saf 15(Suppl, 2):1–8, 2016.
82.
RazjouyanK, DaneshA, KhademiM, Davari-AshtianiR, NoorbakhshS: A comparative study of risperidone and aripiprazole in attention deficit hyperactivity disorder in children under six years old: A randomized double-blind study. Iranian J Pediatrics, 28:e60087, 2018.
83.
RobbAS, AnderssonC, BellocchioEE, ManosG, Rojas-FernandezC, MathewS, MarcusR, OwenR, MankoskiR: Safety and tolerability of aripiprazole in the treatment of irritability associated with autistic disorder in pediatric subjects (6–17 years old): Results from a pooled analysis of 2 studies. Prim Care Companion CNS Disord, 13:PCC.10m01008, 2011.
84.
RubinDM, KreiderAR, MatoneM, HuangY-S, FeudtnerC, RossME, LocalioAR: Risk for incident diabetes mellitus following initiation of second-generation antipsychotics among Medicaid-enrolled youths. JAMA Pediatr, 169:e150285, 2015.
85.
SalleeF, KohegyiE, ZhaoJ, McQuadeR, CoxK, SanchezR, van BeekA, NyilasM, CarsonW, KurlanR: Randomized, double-blind, placebo-controlled trial demonstrates the efficacy and safety of oral aripiprazole for the treatment of Tourette's disorder in children and adolescents. J Child Adolesc Psychopharmacol, 27:771–781, 2017.
86.
SridaranR, NesbitCE: Acute dystonia versus neuroleptic malignant syndrome without fever in an eight-year-old child. Pediatr Emerg Care, 33:38–40, 2017.
87.
StarK, IessaN, AlmandilNB, WiltonL, CurranS, EdwardsIR, WongICK: Rhabdomyolysis reported for children and adolescents treated with antipsychotic medicines: A case series analysis. J Child Adolesc Psychopharmacol, 22:440–451, 2012.
88.
StassinosG, Klein-SchwartzW: Comparison of pediatric atypical antipsychotic exposures reported to U.S. poison centers. Clin Toxicol (Phila), 55:40–45, 2017.
89.
SternAP, TrieuML: A case of antipsychotic-induced hyperglycemia in a child with insulin dependent diabetes mellitus. J Child Adolesc Psychopharmacol, 22:403–404, 2012.
90.
ThabetFI, SweisRT, JosephSA: Aripiprazole-induced seizure in a 3-year-old child: A case report and literature review. Clin Neuropharmacol, 36:29–30, 2013.
91.
TramontinaS, ZeniCP, KetzerCR, PheulaGF, NarvaezJ, RohdeLA: Aripiprazole in children and adolescents with bipolar disorder comorbid with attention-deficit/hyperactivity disorder: A pilot randomized clinical trial. J Clin Psychiatry, 70:756–764, 2009.
92.
van SchalkwykGI, LewisAS, BeyerC, JohnsonJ, van RensburgS, BlochMH: Efficacy of antipsychotics for irritability and aggression in children: A meta-analysis. Expert Rev Neurother, 17:1045–1053, 2017.
93.
VarniJW, HandenBL, Corey-LislePK, GuoZ, ManosG, AmmermanDK, MarcusRN, OwenR, McQuadeRD, CarsonWH, MathewS, MankoskiR: Effect of aripiprazole 2 to 15 mg/d on health-related quality of life in the treatment of irritability associated with autistic disorder in children: A post hoc analysis of two controlled trials. Clin Ther, 34:980–992, 2012.
94.
WangL-J, ChouW-J, ChouM-C, GauSS-F: The effectiveness of aripiprazole for tics, social adjustment, and parental stress in children and adolescents with Tourette's disorder. J Child Adolesc Psychopharmacol, 26:442–448, 2016.
95.
WangS, WeiY-Z, YangJ-H, ZhouY-M, ChengY-H, YangC, ZhengY: The efficacy and safety of aripiprazole for tic disorders in children and adolescents: A systematic review and meta-analysis. Psychiatry Res, 254:24–32, 2017.
96.
WinterfeldU, HeuzeyM-FL, AcquavivaE, MourenM-C, BrionF, BourdonO: Off-label use of psychotropic drugs in paediatrics: a prospective study. 2009. /data/revues/0929693X/v16i9/S0929693X0900267X https://www.em-consulte.com/en/article/223988 (accessed April9, 2019).
97.
YangC-S, HuangH, ZhangL-L, ZhuC-R, GuoQ: Aripiprazole for the treatment of tic disorders in children: a systematic review and meta-analysis. BMC Psychiatry, 15:179, 2015.
98.
YooHK, JoungYS, LeeJ-S, SongDH, LeeYS, KimJ-W, KimB-N, ChoSC: A multicenter, randomized, double-blind, placebo-controlled study of aripiprazole in children and adolescents with Tourette's disorder. J Clin Psychiatry, 74:e772–e780, 2013.
99.
YoonY, WinkLK, PedapatiEV, HornPS, EricksonCA: Weight gain effects of second-generation antipsychotic treatment in autism spectrum disorder. J Child Adolesc Psychopharmacol, 26:822–827, 2016.
100.
ZhengW, LiX-B, XiangY-Q, ZhongB-L, ChiuHFK, UngvariGS, NgCH, LokGKI, XiangY-T: Aripiprazole for Tourette's syndrome: a systematic review and meta-analysis. Hum Psychopharmacol, 31:11–18, 2016.
101.
ZitoJM, BurcuM, McKeanS, WarnockR, KelmanJ: Pediatric use of antipsychotic medications before and after medicaid peer review implementation. JAMA Psychiatry, 75:100–103, 2018.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
